Putting polypills into practice: challenges and lessons learned

The Lancet

Volumn 389, Issue 10073, 2017, Pages 1066-1074

  Webster, Ruth ^a   Castellano, Jose M ^b,c,d   Onuma, Oyere K ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; ESSENTIAL DRUG;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; DRUG EFFECT; DRUG FORMULATION; DRUG INDUSTRY; DRUG QUALITY; DRUG USE; HEALTH SURVEY; HUMAN; KNOWLEDGE BASE; LIFESTYLE MODIFICATION; LOW INCOME COUNTRY; MANUFACTURING INDUSTRY; MIDDLE INCOME COUNTRY; PATIENT ADVOCACY; PATIENT ATTITUDE; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN ATTITUDE; PILL; POLYPHARMACY; POLYPILL; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; REVIEW; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; DRUG APPROVAL; DRUG COMBINATION; FORECASTING; HEALTH PERSONNEL ATTITUDE; LIFESTYLE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG APPROVAL; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUGS, ESSENTIAL; FORECASTING; HUMANS; LIFE STYLE; PATIENT ACCEPTANCE OF HEALTH CARE; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY PREVENTION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REIMBURSEMENT MECHANISMS; SECONDARY PREVENTION;

EID: 85015176282     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30558-5     Document Type: Review

References (39)

1. 1 WHO. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions, 2002, World Health Organization, Geneva.
2. 2 Kellermann, AL, Desai, NR, Obstacles to developing cost-lowering health technology: the inventor's dilemma. JAMA 314 (2015), 1447–1448.
3. 3 Piepoli, MF, Hoes, AW, Agewall, S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
4. 4 WHO. HEARTS technical package for cardiovascular disease management in primary health care. http://www.who.int/cardiovascular_diseases/hearts/Hearts_package.pdf, 2016 (accessed Feb 21, 2017).
5. 5 Huffman, MD, Xavier, D, Perel, P, Polypill uses and evidence to date. Lancet 389 (2017), 953–963.
6. 6 Patel, A, Webster, R, Pragmatic trials for noncommunicable diseases: relieving constraints. PLoS Med, 13, 2016, e1001986.
7. 7 Soliman, E, Mendis, S, Dissanayake, W, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials, 12, 2011, 3.
8. 8 Selak, V, Elley, CR, Bullen, C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ, 348, 2014, g3318.
9. 9 Thom, S, Poulter, N, Field, J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310 (2013), 918–929.
10. 10 Liu, H, Massi, L, Laba, TL, et al. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Circ Cardiovasc Qual Outcomes 8 (2015), 301–308.
11. 11 Laba, TL, Howard, K, Rose, J, et al. Patient preferences for a polypill for the prevention of cardiovascular diseases. Ann Pharmacother 49 (2015), 528–539.
12. 12 Viera, AJ, Sheridan, SL, Edwards, T, Soliman, EZ, Harris, R, Furberg, CD, Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med 52 (2011), 10–15.
13. 13 Bryant, L, Martini, N, Chan, J, et al. Could the polypill improve adherence? The patient perspective. J Prim Health Care 5 (2013), 28–35.
14. 14 Jamison, J, Graffy, J, Mullis, R, Mant, J, Sutton, S, Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study. BMJ Open, 6, 2016, e010458.
15. 15 Virdee, SK, Greenfield, SM, Fletcher, K, McManus, RJ, Hobbs, FD, Mant, J, Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open, 3, 2013, e002498.
16. 16 Virdee, SK, Greenfield, SM, Fletcher, K, McManus, RJ, Mant, J, Patients' views about taking a polypill to manage cardiovascular risk: a qualitative study in primary care. Br J Gen Pract 65 (2015), e447–e453.
17. 17 Wood, F, Salam, A, Singh, K, et al. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open, 5, 2015, e008018.
18. 18 Truelove, M, Patel, A, Bompoint, S, et al. The effect of a cardiovascular polypill strategy on pill burden. Cardiovasc Ther 33 (2015), 347–352.
19. 19 Patel, A, Cass, A, Peiris, D, et al., for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 22 (2015), 920–930.
20. 20 Webster, R, Patel, A, Billot, L, et al., SPACE Collaboration. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. Int J Cardiol 170 (2013), 30–35.
21. 21 Webster, R, Patel, A, Selak, V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 205 (2016), 147–156.
22. 22 Castellano, JM, Sanz, G, Penalvo, JL, et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. J Am Coll Cardiol 64 (2014), 2071–2082.
23. 23 Selak, V, Bullen, C, Stepien, S, et al. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol 23 (2016), 1393–1400.
24. 24 Tamargo, J, Castellano, JM, Fuster, V, The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol 201 (2015), S15–S22.
25. 25 PILL Collaborative Group, Rodgers, A, Patel, A, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One, 6, 2011, e19857.
26. 26 Webster, R, Rodgers, A, Polypill: progress and challenges to global use—update on the trials and policy implementation. Curr Cardiol Rep 17 (2015), 1–8.
27. 27 Yusuf, S, Islam, S, Chow, CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
28. 28 WHO. Global health estimates 2014 summary tables. Deaths by cause, age and sex, 2000–2012, 2014, World Health Organization, Geneva.
29. 29 WHO. Global action plan for the prevention and control of noncommunicable diseases 2013–2020, 2013, World Health Organization, Geneva.
30. 30 WHO. Fixed-dose combinations for HIV/AIDS, tuberculosis and malaria: report of a meeting held 16–18 December 2003, Geneva, 2003, World Health Organization, Geneva, 1–199.
31. 31 Gilks, CF, Crowley, S, Ekpini, R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006), 505–510.
32. 32 Gaziano, TA, Opie, LH, Weinstein, MC, Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368 (2006), 679–686.
33. 33 Goff, DC Jr, Lloyd-Jones, DM, Bennett, G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:suppl 2 (2014), S49–S73.
34. 34 Anderson, KM, Odell, PM, Wilson, PW, Kannel, WB, Cardiovascular disease risk profiles. Am Heart J 121 (1991), 293–298.
35. 35 Hippisley-Cox, J, Coupland, C, Vinogradova, Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336 (2008), 1475–1482.
36. 36 New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines handbook: a summary resource for primary care practitioners, 2005, New Zealand Guidelines Group, Wellington.
37. 37 WHO. Annex 5. Guidelines for registration of fixed-dose combination medicinal products. WHO Expert Committee on specifications for pharmaceutical preparations. WHO Technical Report Series 929. Thirty-ninth Report, 2005, World Health Organization, Geneva.
38. 38 WHO. Essential medicines and health products: prequalification of medicines. Guidance documents. https://extranet.who.int/prequal/content/WHOguidance-documents, 2017 (accessed Feb 21, 2017).
39. 39 González-Juanatey, JR, Mostaza, JM, Lobos, JM, Abarca, B, Llisterri, JL, A step ahead in secondary prevention of cardiovascular risk. consensus document on clinical use of the polypill. Rev Esp Cardiol (Engl ed) 69 (2016), 547–550.